The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models. (October 2020)
- Record Type:
- Journal Article
- Title:
- The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models. (October 2020)
- Main Title:
- The clinical candidate, ASTX029, is a novel, dual mechanism ERK1/2 inhibitor and has potent activity in MAPK-activated cancer cell lines and in vivo tumor models
- Authors:
- Munck, J.
Berdini, V.
Courtin, A.
East, C.
Heightman, T.
Hindley, C.
Kucia-Tran, J.
Lyons, J.
Martins, V.
Muench, S.
Murray, C.
Norton, D.
O'Reilly, M.
Reader, M.
Rees, D.
Rich, S.
Thompson, N.
Wilsher, N.
Woolford, A.
Wallis, N. - Abstract:
- Is Part Of:
- European journal of cancer. Volume 138(2020)Supplement 2
- Journal:
- European journal of cancer
- Issue:
- Volume 138(2020)Supplement 2
- Issue Display:
- Volume 138, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 138
- Issue:
- 1
- Issue Sort Value:
- 2020-0138-0001-0000
- Page Start:
- S53
- Page End:
- Publication Date:
- 2020-10
- Subjects:
- Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/S0959-8049(20)31218-1 ↗
- Languages:
- English
- ISSNs:
- 0959-8049
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 15525.xml